Background: The role of remdesivir in the treatment of patients in hospital with COVID-19
remains ill defined in a global context. The World Health Organization Solidarity randomized …

Purpose This review was aimed to synthesise the best available evidence on the
effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19 …

Remdesivir is an antiviral agent that has shown broad‐spectrum activity, including against
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clinical trials investigating …

Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …

SARS-CoV-2 is causing an increasing number of deaths worldwide because no effective
treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses …

Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …

Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …

Objectives We performed a systematic review and network meta-analysis of randomized
controlled trials (RCTs) to provide updated information regarding the clinical efficacy of …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …